Drug · DIN 02474263
HUMIRA
PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 18, 2020; first marketed August 18, 2020.
- Drug Identification Number (DIN)
- 02474263
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 20 MG | 0.2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 26, 2018: NOC 20660Supplement to a New Drug Submission (SNDS) · New presentation
- March 26, 2018: NOC 20661Supplement to a New Drug Submission (SNDS) · New presentation
Other DINs named HUMIRA
- DIN 02258595 · Marketed
- DIN 02458349 · Marketed
- DIN 02458357 · Marketed
- DIN 02466872 · Approved
- DIN 02474220 · Approved
- DIN 02474255 · Approved